+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 9 Actively Recruiting clinical trials

G

Actively Recruiting

Researchers are evaluating volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma LA-HNSCC who have not experienced disease progression after completing definitive concurrent chemoradiotherapy cCRT. This Phase III study aims to assess the efficacy and safety of volrustomig as a sequential therapy following standard treatment in this patient group. Participants are randomly assigned to one of two groups one group receives volrustomig, while the other undergoes observation without additional treatment. The study is open-label and conducted globally, with the treatment and observation phases occurring after completion of prior chemoradiotherapy. The study period extends up to approximately 8 years to monitor long-term outcomes. During the study, participants will be regularly assessed for progression-free survival, overall survival, and physical functioning, among other measures. Blood samples will be collected to evaluate the presence of anti-drug antibodies and drug pharmacokinetics. Quality of life questionnaires and safety monitoring for adverse events will also be conducted. Participants may be followed for up to 8 years after starting the study to track these outcomes.

Age: 18Years - 130YearsAll GendersPhase 3
306 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of eloralintide in adults who are obese or overweight but do not have type 2 diabetes. This Phase 3 clinical trial aims to understand how eloralintide affects body weight and other health measures over time in this population. Participants will be randomly assigned to receive one of four different doses of eloralintide or a placebo, all given by subcutaneous injection. The main phase of the study lasts about 75 weeks, and participants with prediabetes may continue into an extension phase for an additional 2 years to further assess long-term effects. During the study, participants will have regular visits for assessments including body weight, body fat, waist circumference, blood pressure, blood tests, and questionnaires on overall health. Researchers will monitor changes from baseline up to week 64 and longer for some measures, including the time to develop type 2 diabetes. Safety and medication use will also be tracked throughout the study period.

Age: 18Years +All GendersPhase 3
158 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of inavolisib combined with Phesgo compared to placebo with Phesgo as maintenance treatment after initial therapy in people with untreated HER2-positive advanced breast cancer that has a PIK3CA mutation. This phase III trial focuses on how well the treatments control the disease and their side effects. Participants first receive induction therapy with Phesgo plus taxane-based chemotherapy. Afterward, they receive maintenance therapy with either inavolisib plus Phesgo or placebo plus Phesgo in 21-day cycles. Phesgo is given by subcutaneous injection every 3 weeks, while inavolisib or placebo tablets are taken daily on days 1 to 21 of each cycle. Optional endocrine therapy may also be provided according to standard care. During the study, participants undergo regular assessments including tumor evaluations, heart function tests, laboratory tests, and quality of life questionnaires. Researchers monitor progression-free survival up to about 40 months and overall survival and other outcomes up to approximately 111 months. Participants are followed closely for adverse events and drug levels. The total study duration may extend up to nearly 10 years, with visits scheduled throughout treatment and follow-up periods.

Age: 18Years +All GendersPhase 3
192 locations
M

Actively Recruiting

Researchers are collecting real-world data on the safety and performance of AtriCure devices used to treat Inappropriate Sinus Tachycardia IST and Postural Tachycardia Syndrome POTS. This observational registry includes both retrospective and prospective data from multiple centers in the US and internationally, aiming to better understand outcomes following these treatments. The study involves patients who have either undergone or are scheduled to have epicardial and endocardial hybrid ablation procedures using commercially available AtriCure devices to target cardiac tissue for IST or POTS. There are no experimental drugs or placebos the study focuses on monitoring the real-world use of these devices. Participants medical records and outcomes will be observed over a period of five years to capture long-term data on device use and treatment results. Researchers will collect information regarding the procedures, patient safety, and device performance without altering standard medical care. Participation includes providing informed consent and allowing access to relevant health information for study purposes.

Age: 18Years - 100YearsAll Genders
15 locations
E

Actively Recruiting

Acute sinus infections, also called acute rhinosinusitis ARS, affect about 15% of adults annually and are a common reason for antibiotic prescriptions despite most cases being caused by viruses. This research aims to understand which patients with ARS truly benefit from antibiotics and other treatments, improving care by identifying subgroups that respond best to specific therapies. The study is a large, pragmatic, randomized controlled trial enrolling adults aged 18 to 75 with symptoms consistent with ARS. Participants enter two phases Phase 1 is a waiting period of up to 9 days with options for supportive care, during which symptom progress is monitored. Those who do not improve or who meet certain criteria move to Phase 2, where they are randomly assigned to one of four groups receiving either amoxicillinclavulanate, placebo antibiotic, amoxicillinclavulanate plus budesonide nasal spray, or placebo antibiotic plus budesonide. Treatments are given over 7 to 14 days, with dosing schedules including oral antibiotics twice daily and budesonide nasal spray once daily. Throughout both phases, participants complete daily diaries and periodic follow-ups to track symptom changes, supportive care use, and side effects. Researchers measure symptom improvement from day 1 to day 3 in Phase 2 as the primary outcome, along with additional assessments of quality of life, work productivity, adherence, and adverse events. The total study period includes up to 9 days of observation and 14 days of randomized treatment with ongoing monitoring to better target effective management for ARS.

Age: 18Years - 75YearsAll GendersPhase 4
7 locations
E

Actively Recruiting

Researchers are studying the use of a medical procedure involving the Bullfrog Micro-Infusion Device to deliver the anti-inflammatory drug dexamethasone sodium phosphate injection locally around deep veins after deep vein thrombosis DVT recanalization. This study focuses on patients who had DVT symptoms for up to 14 days before the recanalization. The goal is to evaluate whether this local anti-inflammatory treatment helps prevent re-thrombosis and improves symptoms for up to 24 months after the initial procedure. Participants are randomly assigned to receive either the perivascular dexamethasone treatment or a saline sham control delivered around the target vein segment using the catheter device. The study compares these two groups in a quadruple-masked design. Treatments are given following successful recanalization and removal of the acute thrombus from the femoropopliteal veins, which may extend into the iliac veins. During the study, participants will be monitored for the rate of vessel patency, progression to post-thrombotic syndrome, and major adverse events at specified time points up to 6 months and 30 days respectively. They will also follow prescribed anticoagulant and antiplatelet regimens post-procedure. Follow-up includes completion of questionnaires and study visits over up to 24 months to assess outcomes and safety under the lead sponsor Mercator MedSystems, Inc.

Age: 18Years - 89YearsAll GendersPhase 2
22 locations
L

Actively Recruiting

Researchers are evaluating the long-term reliability and performance of cardiac rhythm products marketed by Medtronic. This observational study focuses on devices such as leads, implantable pulse generators, implantable cardioverter defibrillators, and cardiac resynchronization therapy devices used for conditions like arrhythmia, bradycardia, heart failure, and sinus tachycardia. The study aims to analyze product survival probabilities and monitor lead-related complications over time. Participants include individuals who have received or will receive Medtronic market-released cardiac devices for pacing, sensing, or defibrillation. The study includes products implanted as part of routine care or participants from prior qualifying studies. Data is collected from the time of implantation and continues until the device is removed from service, the patient exits the study, or passes away. Enrollment criteria also require consent for access to health information. During the study, participants device performance is monitored through follow-up data collection. Researchers assess complications related to the implanted leads and track device status over long periods, potentially spanning several years. The study does not involve additional treatments but relies on routine clinical follow-up and health information review. The total duration extends up to December 2040, allowing comprehensive long-term evaluation of device performance.

All AgesAll Genders
338 locations
M

Actively Recruiting

This observational registry study is designed to continuously evaluate and periodically report on the safety and effectiveness of Medtronic market-released medical products. It aims to support patients, hospitals, clinicians, regulatory bodies, payers, and the medical industry by streamlining clinical surveillance and enhancing performance assessment with minimal burden. Participants include patients who have received or are intended to receive an eligible Medtronic product. The registry collects data related to various conditions such as cardiac rhythm disorders, neurological disorders, cardiovascular disorders, and several others, with ongoing monitoring every 6 to 12 months depending on the therapy. During the study, participants provide consent and data is collected during routine care and follow-up visits. The research team reviews safety and effectiveness outcomes regularly to understand product performance over time. The study is planned to continue until January 2040, allowing for long-term monitoring and reporting.

All AgesAll Genders
402 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the SELUTION SLR14 Drug Eluting Balloon DEB compared to plain uncoated balloon angioplasty in patients with peripheral arterial disease PAD affecting the below-the-knee BTK arteries, specifically in those with chronic limb-threatening ischemia CLTI. The study aims to show that the SELUTION SLR14 DEB has better efficacy and similar safety compared to the uncoated balloon treatment. Participants are adults aged 18 years or older with documented CLTI and significant narrowing in BTK arteries. The trial randomly assigns participants to one of two groups one receiving the SELUTION SLR14 DEB and the other receiving plain balloon angioplasty. Both are non-surgical procedures where a catheter inflates a balloon to open narrowed arteries below the knee. Treatments target specific lesions in BTK arteries and must meet detailed angiographic criteria. The study uses a single-blind design and includes follow-up assessments over several years. Participants will undergo evaluations at multiple time points including 30 days, 6 months, and up to 36 months after treatment. Assessments include clinical improvement, amputation rates, wound healing, imaging, and quality of life measures. Safety endpoints are monitored early, while efficacy outcomes are tracked long term. The study also evaluates device and procedural success immediately after treatment. Overall participation may last over three years to gather comprehensive safety and effectiveness data.

Age: 18Years +All GendersPhase Not Applicable
48 locations